

해외 바이오의약품 임상 현황 (2020.03.23~2020.03.29)

한국바이오의약품협회, 2020.3.31.  
출처: ClinicalTrials.gov

○ 미국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04081337	A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide	Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT03993327	An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody M5A Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04196491	A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)	Multiple Myeloma	Biological: bb2121 carfilzomib Drug: Fludarabine Drug: Cyclophosphamide Drug: Lenalidomide	Celgene	Phase 1
NCT04274907	A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression	Non Small Cell Lung Cancer Cancer	Drug: Venetoclax Drug: Pembrolizumab	AbbVie	Phase 1

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	Corona Virus Infection	Drug: Sarilumab	Assistance Publique - Hôpital de Paris	Phase 2 Phase 3

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04303741	A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC	Breast Cancer	Drug: Camrelizumab Drug: Apatinib Drug: Eribulin	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
NCT04276896	Immunity and Safety of Covid-19 Synthetic Minigene Vaccine	Pathogen Infection Covid-19 Infection	Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs	Shenzhen Geno-Immune Medical Institute Shenzhen Third People's Hospital Shenzhen Second People's Hospital	Phase 1 Phase 2